Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 12/2015

01.12.2015 | Review – Clinical Oncology

Patient-reported outcomes in randomised controlled trials of colorectal cancer: an analysis determining the availability of robust data to inform clinical decision-making

verfasst von: Jonathan R. Rees, Katie Whale, Daniel Fish, Peter Fayers, Valentina Cafaro, Andrea Pusic, Jane M. Blazeby, Fabio Efficace

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 12/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Randomised controlled trials (RCTs) are the most robust study design measuring outcomes of colorectal cancer (CRC) treatments, but to influence clinical practice trial design and reporting of patient-reported outcomes (PROs) must be of high quality. Objectives of this study were as follows: to examine the quality of PRO reporting in RCTs of CRC treatment; to assess the availability of robust data to inform clinical decision-making; and to investigate whether quality of reporting improved over time.

Methods

A systematic review from January 2004–February 2012 identified RCTs of CRC treatment describing PROs. Relevant abstracts were screened and manuscripts obtained. Methodological quality was assessed using International Society for Quality of Life Research—patient-reported outcome reporting standards. Changes in reporting quality over time were established by comparison with previous data, and risk of bias was assessed with the Cochrane risk of bias tool.

Results

Sixty-six RCTs were identified, seven studies (10 %) reported survival benefit favouring the experimental treatment, 35 trials (53 %) identified differences in PROs between treatment groups, and the clinical significance of these differences was discussed in 19 studies (29 %). The most commonly reported treatment type was chemotherapy (n = 45; 68 %). Improvements over time in key methodological issues including the documentation of missing data and the discussion of the clinical significance of PROs were found. Thirteen trials (20 %) had high-quality reporting.

Conclusions

Whilst improvements in PRO quality reporting over time were found, several recent studies still fail to robustly inform clinical practice. Quality of PRO reporting must continue to improve to maximise the clinical impact of PRO findings.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat Cocks K, King MT, Velikova G, Fayers PM, Brown JM (2008) Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30 data in randomised controlled trials. Eur J Cancer 44:1793–1798. doi:10.1016/j.ejca.2008.05.008 CrossRefPubMed Cocks K, King MT, Velikova G, Fayers PM, Brown JM (2008) Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30 data in randomised controlled trials. Eur J Cancer 44:1793–1798. doi:10.​1016/​j.​ejca.​2008.​05.​008 CrossRefPubMed
Zurück zum Zitat Coulman KD, Abdelrahman T, Owen-Smith A, Andrews RC, Welbourn R, Blazeby JM (2013) Patient-reported outcomes in bariatric surgery: a systematic review of standards of reporting. Obes Rev Off J Int Assoc Study Obes. doi:10.1111/obr.12041 Coulman KD, Abdelrahman T, Owen-Smith A, Andrews RC, Welbourn R, Blazeby JM (2013) Patient-reported outcomes in bariatric surgery: a systematic review of standards of reporting. Obes Rev Off J Int Assoc Study Obes. doi:10.​1111/​obr.​12041
Zurück zum Zitat de Kort SJ, Willemse PHB, Habraken JM, de Haes HCJM, Willems DL, Richel DJ (2006) Quality of life versus prolongation of life in patients treated with chemotherapy in advanced colorectal cancer: a review of randomized controlled clinical trials. Eur J Cancer 42:835–845. doi:10.1016/j.ejca.2005.10.026 CrossRefPubMed de Kort SJ, Willemse PHB, Habraken JM, de Haes HCJM, Willems DL, Richel DJ (2006) Quality of life versus prolongation of life in patients treated with chemotherapy in advanced colorectal cancer: a review of randomized controlled clinical trials. Eur J Cancer 42:835–845. doi:10.​1016/​j.​ejca.​2005.​10.​026 CrossRefPubMed
Zurück zum Zitat Denlinger CS, Barsevick AM (2009) The challenges of colorectal cancer survivorship. J Natl Compr Cancer Netw JNCCN 7:883–893 (quiz 894) PubMed Denlinger CS, Barsevick AM (2009) The challenges of colorectal cancer survivorship. J Natl Compr Cancer Netw JNCCN 7:883–893 (quiz 894) PubMed
Zurück zum Zitat Douillard JY et al (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28:4697–4705. doi:10.1200/JCO.2009.27.4860 CrossRefPubMed Douillard JY et al (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28:4697–4705. doi:10.​1200/​JCO.​2009.​27.​4860 CrossRefPubMed
Zurück zum Zitat Ducreux M et al (2011) Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. Int J Cancer 128:682–690. doi:10.1002/ijc.25369 CrossRefPubMed Ducreux M et al (2011) Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. Int J Cancer 128:682–690. doi:10.​1002/​ijc.​25369 CrossRefPubMed
Zurück zum Zitat Efficace F, Bottomley A, Osoba D, Gotay C, Flechtner H, D’Haese S, Zurlo A (2003) Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials—Does HRQOL evaluation in prostate cancer research inform clinical decision making? J Clin Oncol 21:3502–3511. doi:10.1200/JCO.2003.12.121 CrossRefPubMed Efficace F, Bottomley A, Osoba D, Gotay C, Flechtner H, D’Haese S, Zurlo A (2003) Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials—Does HRQOL evaluation in prostate cancer research inform clinical decision making? J Clin Oncol 21:3502–3511. doi:10.​1200/​JCO.​2003.​12.​121 CrossRefPubMed
Zurück zum Zitat Efficace F, Bottomley A, Vanvoorden V, Blazeby JM (2004) Methodological issues in assessing health-related quality of life of colorectal cancer patients in randomised controlled trials. Eur J Cancer 40:187–197CrossRefPubMed Efficace F, Bottomley A, Vanvoorden V, Blazeby JM (2004) Methodological issues in assessing health-related quality of life of colorectal cancer patients in randomised controlled trials. Eur J Cancer 40:187–197CrossRefPubMed
Zurück zum Zitat Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) GLOBOCAN 2008, Cancer incidence and mortality worldwide: IARC CancerBase No. 10. International Agency for Research on Cancer. http://globocan.iarc.fr. Accessed 23 Oct 2013 Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) GLOBOCAN 2008, Cancer incidence and mortality worldwide: IARC CancerBase No. 10. International Agency for Research on Cancer. http://​globocan.​iarc.​fr. Accessed 23 Oct 2013
Zurück zum Zitat Hedges LV, Olkin I (1985) Statistical methods for meta-analysis. Academic Press, Orlando Hedges LV, Olkin I (1985) Statistical methods for meta-analysis. Academic Press, Orlando
Zurück zum Zitat Higgins JPT, Green S (eds) (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration. www.cochrane-handbook.org Higgins JPT, Green S (eds) (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration. www.​cochrane-handbook.​org
Zurück zum Zitat Jayne DG, Brown JM, Thorpe H, Walker J, Quirke P, Guillou PJ (2005) Bladder and sexual function following resection for rectal cancer in a randomized clinical trial of laparoscopic versus open technique. Br J Surg 92:1124–1132. doi:10.1002/bjs.4989 CrossRefPubMed Jayne DG, Brown JM, Thorpe H, Walker J, Quirke P, Guillou PJ (2005) Bladder and sexual function following resection for rectal cancer in a randomized clinical trial of laparoscopic versus open technique. Br J Surg 92:1124–1132. doi:10.​1002/​bjs.​4989 CrossRefPubMed
Zurück zum Zitat Juni P, Holenstein F, Sterne J, Bartlett C, Egger M (2002) Direction and impact of language bias in meta-analyses of controlled trials: empirical study. Int J Epidemiol 31:115–123CrossRefPubMed Juni P, Holenstein F, Sterne J, Bartlett C, Egger M (2002) Direction and impact of language bias in meta-analyses of controlled trials: empirical study. Int J Epidemiol 31:115–123CrossRefPubMed
Zurück zum Zitat Lee CW, Chi KN (2000) The standard of reporting of health-related quality of life in clinical cancer trials. J Clin Epidemiol 53:451–458CrossRefPubMed Lee CW, Chi KN (2000) The standard of reporting of health-related quality of life in clinical cancer trials. J Clin Epidemiol 53:451–458CrossRefPubMed
Zurück zum Zitat Lembersky BC et al (2006) Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 24:2059–2064. doi:10.1200/JCO.2005.04.7498 CrossRefPubMed Lembersky BC et al (2006) Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 24:2059–2064. doi:10.​1200/​JCO.​2005.​04.​7498 CrossRefPubMed
Zurück zum Zitat Main BG, Strong S, McNair AG, Falk SJ, Crosby T, Blazeby JM (2014) Reporting outcomes of definitive radiation-based treatment for esophageal cancer: a review of the literature Diseases of the esophagus: official journal of the International Society for Diseases of the Esophagus/ISDE. doi:10.1111/dote.12168 Main BG, Strong S, McNair AG, Falk SJ, Crosby T, Blazeby JM (2014) Reporting outcomes of definitive radiation-based treatment for esophageal cancer: a review of the literature Diseases of the esophagus: official journal of the International Society for Diseases of the Esophagus/ISDE. doi:10.​1111/​dote.​12168
Zurück zum Zitat Moher D, Pham B, Klassen TP, Schulz KF, Berlin JA, Jadad AR, Liberati A (2000) What contributions do languages other than English make on the results of meta-analyses? J Clin Epidemiol 53:964–972CrossRefPubMed Moher D, Pham B, Klassen TP, Schulz KF, Berlin JA, Jadad AR, Liberati A (2000) What contributions do languages other than English make on the results of meta-analyses? J Clin Epidemiol 53:964–972CrossRefPubMed
Zurück zum Zitat Moher D et al (2010) CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. doi:10.1136/bmj.c869 Moher D et al (2010) CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. doi:10.​1136/​bmj.​c869
Zurück zum Zitat Peeters KC et al (2005) Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients—a Dutch colorectal cancer group study. J Clin Oncol 23:6199–6206. doi:10.1200/JCO.2005.14.779 CrossRefPubMed Peeters KC et al (2005) Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients—a Dutch colorectal cancer group study. J Clin Oncol 23:6199–6206. doi:10.​1200/​JCO.​2005.​14.​779 CrossRefPubMed
Zurück zum Zitat Peeters M et al (2010) Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28:4706–4713. doi:10.1200/JCO.2009.27.6055 CrossRefPubMed Peeters M et al (2010) Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28:4706–4713. doi:10.​1200/​JCO.​2009.​27.​6055 CrossRefPubMed
Zurück zum Zitat Staquet M, Berzon R, Osoba D, Machin D (1996) Guidelines for reporting results of quality of life assessments in clinical trials. Qual Life Res 5:496–502CrossRefPubMed Staquet M, Berzon R, Osoba D, Machin D (1996) Guidelines for reporting results of quality of life assessments in clinical trials. Qual Life Res 5:496–502CrossRefPubMed
Zurück zum Zitat Stephens RJ et al (2010) Impact of short-course preoperative radiotherapy for rectal cancer on patients’ quality of life: data from the Medical Research Council CR07/National Cancer Institute of Canada Clinical Trials Group C016 randomized clinical trial. J Clin Oncol 28:4233–4239. doi:10.1200/JCO.2009.26.5264 CrossRefPubMed Stephens RJ et al (2010) Impact of short-course preoperative radiotherapy for rectal cancer on patients’ quality of life: data from the Medical Research Council CR07/National Cancer Institute of Canada Clinical Trials Group C016 randomized clinical trial. J Clin Oncol 28:4233–4239. doi:10.​1200/​JCO.​2009.​26.​5264 CrossRefPubMed
Zurück zum Zitat Thong MS, Mols F, Wang XS, Lemmens VE, Smilde TJ, van de Poll-Franse LV (2013) Quantifying fatigue in (long-term) colorectal cancer survivors: a study from the population-based patient reported outcomes following initial treatment and long term evaluation of survivorship registry. Eur J Cancer 49:1957–1966. doi:10.1016/j.ejca.2013.01.012 PubMedCentralCrossRefPubMed Thong MS, Mols F, Wang XS, Lemmens VE, Smilde TJ, van de Poll-Franse LV (2013) Quantifying fatigue in (long-term) colorectal cancer survivors: a study from the population-based patient reported outcomes following initial treatment and long term evaluation of survivorship registry. Eur J Cancer 49:1957–1966. doi:10.​1016/​j.​ejca.​2013.​01.​012 PubMedCentralCrossRefPubMed
Metadaten
Titel
Patient-reported outcomes in randomised controlled trials of colorectal cancer: an analysis determining the availability of robust data to inform clinical decision-making
verfasst von
Jonathan R. Rees
Katie Whale
Daniel Fish
Peter Fayers
Valentina Cafaro
Andrea Pusic
Jane M. Blazeby
Fabio Efficace
Publikationsdatum
01.12.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 12/2015
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-015-1970-x

Weitere Artikel der Ausgabe 12/2015

Journal of Cancer Research and Clinical Oncology 12/2015 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.